

*Treatment with SGLT2 inhibitors, GLP-1 & GIP receptor agonists, PPAR-gamma agonists (pioglitazone), RAS inhibitors, or mineralocorticoid receptor antagonism*

**RISK FACTOR AMELIORATION occurring:**  
**(a) INDEPENDENTLY OF TREATMENT EFFECTS ON LIVER DISEASE and (b) DEPENDENT ON IMPROVEMENTS IN LIVER DISEASE**

**Excess body fat**  
Potential treatment effect: weight loss with reductions in visceral and subcutaneous fat depots


**Cardiometabolic risk factors**  
Potential treatment effect: improvements in blood pressure, atherogenic dyslipidemia, dysglycemia, and insulin resistance

**Liver lipid metabolism**  
Potential treatment effect: decreased hepatic fat content and lipotoxicity


**Low-grade inflammation**  
Potential treatment effect: decreased C-reactive protein, interleukin-6, TNF-alpha, and other acute-phase proteins

**Prothrombotic state**  
Potential treatment effect: decreased factor VII, fibrinogen, tissue factor, plasminogen activator inhibitor-1, and other fibrinolytic factors


**Other risk factors**  
Potential treatment effect: increased adiponectin, decreased reactive oxygen species, and improved proteinuria



**MASLD**



**MASLD attenuation or amelioration**



**Improvements in cardiovascular and renal risk factors**

**Effects of drug treatments on risk factors for liver and kidney disease**